European markets expected to nosedive after Fed signals fewer rate cuts ahead; BOE decision in focus

European markets expected to nosedive after Fed signals fewer rate cuts ahead; BOE decision in focus


European markets are expected to nosedive at the open Thursday, following their global counterparts lower after the U.S. Federal Reserve signalled yesterday that few rates cuts are on the horizon.

The U.K.’s FTSE 100 index is expected to open 84 points lower at 8,105, Germany’s DAX down 265 points at 19,993, France’s CAC down 105 points at 7,284 and Italy’s FTSE MIB down 507 points at 33,876, according to data from IG.

The anticipated lower open for Europe comes follows a Wednesday sell-off on Wall Street after the Fed, which cut its overnight borrowing rate by 25 basis points to a target range of 4.25% to 4.5%, signalled there will likely only be two rate cuts in 2025, rather than the four cuts indicated in its previous forecast.

“We moved pretty quickly to get to here, and I think going forward obviously we’re moving slower,” Fed Chair Jerome Powell said at the post-meeting press conference.

The comments prompted panic on Wall Street, with U.S. stocks plunging as bull market sentiment was dealt a blow. Overnight, Asia-Pacific markets and currencies also fell.

There’s more central bank action in Europe Thursday with monetary policy decisions due from the Bank of England and Norges Bank, the central bank of Norway.

Investors will also be keeping an eye on European new passenger car registration data, Germany’s Gfk consumer confidence figures and Spanish trade data to gauge the health of the region’s economy.

— CNBC’s Jeff Cox contributed to this market report



Source

Merck shells out  billion for London-based lung therapy firm Verona
World

Merck shells out $10 billion for London-based lung therapy firm Verona

Bloomberg | Bloomberg | Getty Images Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm’s respiratory treatment portfolio in a bid to diversify its revenue source beyond blockbuster cancer drug. Merck has been leaning on its aging cancer immunotherapy Keytruda, the world’s top-selling prescription medicine, […]

Read More
Singapore state investor Temasek is rethinking defense as a strategic ESG bet
World

Singapore state investor Temasek is rethinking defense as a strategic ESG bet

Defense stocks are booming — and according to one of Asia’s biggest investors, allocating capital to the sector doesn’t mean having to abandon ESG initiatives. Speaking to CNBC’s Martin Soong on Wednesday, Rohit Sipahimalani, chief investment officer at Singapore’s state investment fund Temasek, said his team were looking at opportunities in the European defense sector. […]

Read More
Shares of Ray-Ban maker EssilorLuxottica jump 6% on reported Meta stake in AI push
World

Shares of Ray-Ban maker EssilorLuxottica jump 6% on reported Meta stake in AI push

Smart Ray-Ban Glasses, on June 16, 2024, in Caen, Normandy, France. Nurphoto | Getty Images Shares of Ray-Ban maker EssilorLuxottica almost 6% on Wednesday on reports that Meta has taken a minority stake in the company amid growing appetite for AI-powered wearable devices. Meta reportedly bought a stake worth around 3 billion euros ($3.51 billion) […]

Read More